



Chuck DeSmith
Deputy Fire Chief, Renton, WA

Regenexx provider patient

“As a fire chief, I didn’t want to go through surgery, possible infection, and extended recovery or be put on any medications.

A lot of our young firefighters feel the same way—whether it’s a shoulder, knee, or back injury.

What the Regenexx benefit provides is fantastic.”

References

1. Khoshakhlagh AH, Al Sulaie S, Mirzahasseininejad M, et al. Occupational stress and musculoskeletal disorders in firefighters: the mediating effect of depression and job burnout. *Sci Rep.* 2024;14(1):4649.

2. Dworsky M, Seabury SA, Broten N. The frequency and economic impact of musculoskeletal disorders for California firefighters: trends and outcomes over the past decade. *Rand Health Q.* 2021;9(2):4.

3. Validation Institute. *Validation Report.* Published 2023. Accessed May 14, 2024.

4. Source: Regenexx data on file.

© 2025 Regenexx Corporate. All rights reserved. 1/25

The Regenexx Benefit for Firefighters

MSK injuries are firefighters’ #1 occupational hazard.^{1,2}

Unfortunately, firefighter MSK injuries and related costly surgeries can often lead to **physical, economic,** and even **societal consequences.¹**

Innovation + Impact

The good news is, another option exists: The Regenexx benefit provides **non-surgical solutions** using **regenerative therapy.** These proprietary methods have been developed since 2005 and are both **innovative** and **impactful.**

An Innovative Option

- Uses precise injections of **patient’s own cells**
- Up to **70% less expensive** and typically **shorter recovery time** than surgery³
- Can **reduce unnecessary surgery** by up to 70%³

The Regenexx Benefit Impact on Firefighters⁴

Total cost savings:
~\$4MM

Total surgeries avoided:
>300

Cost to add the Regenexx benefit:
\$0

Note: Data provided in aggregate.

Please see disclaimers on page 2.

Learn More

Patients often characterize Regenexx's non-surgical treatment options as "stem cell" or "regenerative medicine" procedures using Regenexx lab processes. For more information about these terms and how Regenexx defines them, please visit <https://regenexx.com/our-approach/stem-cells/>.

Procedures using Regenexx injectates have a success and failure rate. Patient reviews and testimonials in this document should not be interpreted as a statement on the effectiveness of treatments for anyone else.

This testimonial reflects the real-life experience of this patient with the Regenexx protocol but is not necessarily typical of what you or any other patient might experience. Individual results of the procedures using Regenexx lab processes will vary depending on a number of factors, including your diagnosis, the severity of your condition, your overall health, and others. To better understand what large numbers of patients experience on average, please visit <https://regenexx.com/results/> and inquire with a physician within the licensed Regenexx network near you.

Cost savings estimates: Physicians within the licensed Regenexx network indicate the surgical procedure for which Regenexx provider patients are a candidate. The Regenexx Corporate Program then measures the actual cost of the procedure using Regenexx lab processes against the cost of the surgical alternative. While the Regenexx Corporate Program does post service reviews and assess a percentage of Regenexx provider patients, not all these cases have been verified by a third party. Fair cost estimates based on Denver, CO ZIP code. In some cases, a generic "arthroscopy" cost estimate had to be used when a detailed condition-specific estimate was unavailable.

Long-term outcomes and cost savings: In the Regenexx knee OA RCT, 12% of Regenexx providerpatients decided to get total knee arthroplasty (TKA) despite treatment at 2 years. In an analysis of the Regenexx Patient Registry (100 Regenexx provider patients, 100 charts reviewed, and 100% response rate), 14.8% of Regenexx provider patients converted to TKA at 1-2 years when Regenexx provider patients were TKA candidates. Failure rates from rotator cuff tear at 2 years were 10%, which are similar to the registry data. The failure rate of rotator cuff repair for full thickness tears is higher, quoted as approximately 20%. Regenexx assumes that Regenexx provider patients treated with Perc-RC repair who were unhappy with their results would convert to a surgical repair at a rate of 10%. Since all procedures using Regenexx lab processes have a failure rate, the Regenexx Corporate Program can provide detailed cost savings models for a number of common procedures using Regenexx lab processes performed. For more information about outcomes for procedures using Regenexx lab processes, review the Regenexx Patient Registry or Regenexx published research.

The information provided by Regenexx is for informational purposes only and is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment. Regenexx is not a teaching institution or medical practice, and does not engage in the training of physicians or the practice of medicine. Physicians listed on the Regenexx websites are independent contractors who have licensed certain Regenexx intellectual property. Nothing on the Regenexx webpages, the Regenexx blog, any informational videos, or other marketing materials should be interpreted as endorsing a particular physician or establishing an employer-employee, partnership, or agency relationship between Regenexx and any physician.

**Contact a Regenexx Corporate
Sales Team Member**



Regenexx Corporate
6151 Thornton Avenue, Suite 400
Des Moines, IA 50321
877-341-5968